Simple blood test could offer hope to patients with treatment-resistant lupus
It is hoped the test, which looks for certain biomarkers in the blood, could help these patients get access to a combination therapy on the health service in the future.
Previous studies have shown patients with treatment-resistant lupus who are positive for the biomarker are 17 times more likely to respond to the drugs, which are available on the NHS but not currently used together.
As part of a £1.7 million trial – known as Stratify Lupus – experts will test the blood of people with lupus that has not responded to conventional therapies such as steroids or immune suppressants.
If they are shown to have the biomarker, researchers will give them either the combination therapy or placebo.
Michael Ehrenstein, consultant rheumatologist at University College London Hospitals and professor of experimental rheumatology at University College London (UCL), is leading the research.
He said: 'If the results are positive then we would apply to allow patients who are positive for the biomarker to receive the combination therapy on the NHS.
'Targeting the patients most likely to benefit from this treatment should make it deliverable on the NHS and improve patient access and outcomes.'
The study will begin in spring 2026 at 16 hospitals across the UK and is expected to finish in 2029.
Lupus is a chronic autoimmune condition where the body's immune system mistakenly attacks healthy tissues and organs.
Prof Ehrenstein's previous research found a combination of the drugs rituximab and belimumab was able to bring lupus under control, and significantly reduce severe flare-ups in some, but not all, patients.
Both drugs are treatment options for lupus patients, but are not used in combination.
They are targeted therapies known as monoclonal antibodies.
These are lab-produced identical copies of a single type of antibody, which are the proteins produced by the immune system to attack the likes of bacteria and viruses.
Prof Ehrenstein's team identified a biomarker in the blood of about half of lupus patients who were resistant to conventional treatment.
Known as IgA2 anti-dsDNA, those with the biomarker were 17 times more likely to respond to a combination of rituximab and belimumab compared to rituximab alone.
It is estimated that up to 69,000 people in the UK have lupus, which mostly affects women and those of African, Caribbean and Asian descent.
It can range from mild to severe, with symptoms including joint pain, skin problems, fatigue and inflammation of major organs.
People often take drugs for life, ranging from steroid tablets and injections, or other immunosuppressant or biological medicines.
Prof Ehrenstein added: 'To have a positive result in a personalised medicine trial for lupus would be globally significant, not only for the biomarker and treatment combination, but also the success of this targeted approach.
'Everyone talks about personalised medicine, but so far this goal has not been achieved in inflammatory/autoimmune rheumatic diseases.
'Stratify Lupus will be the first biomarker enrichment trial for lupus, which is a real coup for UK research.'
The study is being funded by the charity Versus Arthritis and the Efficacy and Mechanism Evaluation (EME) Programme, a partnership between the National Institute for Health and Care Research (NIHR) and the Medical Research Council (MRC).
Professor Lucy Donaldson, director of research at Versus Arthritis, said: 'This major trial holds real promise of a better future for those living with lupus, which particularly affects underserved people.
'Too few advances have been made in tackling the devastating disease which mainly affects women, in particular women of African and Caribbean heritage, in the prime of their lives.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
South Wales Argus
33 minutes ago
- South Wales Argus
Weight loss jabs could be transformative, says outgoing NHS England official
Cholesterol-busting statins are one of the most commonly prescribed drugs in the UK, with around seven to eight million people taking them to cut their chance of heart attack and stroke. An estimated 1.5 million are taking weight loss jabs in the UK. Professor Sir Stephen Powis, the outgoing medical director of NHS England, said the NHS needs to go 'further and faster' to 'turn the tide' on rising levels of obesity. Later this month GPs in England will be allowed to prescribe mounjaro, also known as tirzepatide, for the first time. Patients previously needed to access the drugs through a special weight loss service. Speaking at the NHS ConfedExpo conference in Manchester, Sir Stephen hailed the rollout in GP surgeries as an 'exciting milestone' and said NHS officials are also examining ways to 'broaden access to the drugs'. Around 29% of adults in the UK are obese. Sir Stephen said: 'Right now, obesity is estimated to cost the NHS approximately £11.4 billion every year – this financial burden is unsustainable for the NHS and wider economy. 'We have to turn the tide. We have to and will go further, and faster. 'In just a few years from now, some of today's weight loss drugs will be available at much lower cost. This could completely transform access to these innovative treatments. 'But we will and must be guided by the evidence base and must do this safely and sustainably, in a way that ensures that we are equipped as a health service to deal with the demand.' He said he is not 'starry-eyed' about weight loss drugs, adding they are 'no silver bullet'. He told reporters: 'These medicines can be harmful if they are prescribed without the right checks and wraparound care – they can have side effects, including nausea, dehydration and inflammation of the pancreas, and a worrying number of people are continuing to access them without appropriate checks via the internet. 'We are ambitious and determined to explore different methods of delivery and strengthen the evidence base and will do so alongside this phased rollout, but this is a historic first step in widening access, with 220,000 people set to benefit from the rollout over the first three years. 'So I think over time it's highly likely that they will become more widespread, the evidence base will increase, we will learn better how to deploy them, we'll learn how long people need to be on them, and in terms of weight reduction, how much weight reduction is maintained once people come off – that's a big unknown. 'We see this every time we have a new class of drugs in the early days. But there's still much more to learn. 'There will be more drugs coming on the market; there will be different prices for drugs, we will get to generics, which means that prices will fall. 'We have been through this with statins, and the use of statins is now very different from when they first came out, and I've no doubt that will be the same for these drugs. 'So it's very exciting, but we're in the foothills of learning how to use them.' Asked about statins, Sir Stephen said: 'So firstly, obesity is associated with a whole set of conditions (such as) kidney disease, cardiovascular disease, respiratory conditions. 'So in reducing weight, you will, by the very nature of doing that, be reducing the risk of a whole set of difficult conditions and aiding with their management where people already have them. 'Whether the drugs have effects beyond that, I think, is a research question, and there will be an evidence base being generated. 'And it's not completely unusual for drugs over time to be found to have effects that go over and beyond what they were initially designed for. 'So I think we will wait and see. But obviously, the first task, amongst all the excitement and all the discussion and debate, is to actually get on and deploy tirzepatide in particular. 'We have been focused on getting this rolled out by the end of this month… and that is going to be a really exciting milestone. 'It's going to be a very exciting journey, and there will be things on the way that we haven't expected.' Sir Stephen Powis (Lucy North/PA) He added: 'We set out the our plan for uptake – Nice (National Institute for Health and Care Excellence) have asked for a review of that after three years, which is quite right, because it's quite a long horizon. 'Cost is one element of that, but I think we will learn more about the outcomes that these drugs are driving in terms of lower cardiovascular events and reducing the conditions that we know associated with obesity. 'So absolutely, cost is one element of that, but it's not the only element. We want to look carefully at what the science tells us.' Sir Stephen added: 'When I look back when dialysis came in, we didn't use dialysis for older people. Over years the technology improved, we got more confident, more people were able to access the treatment. 'So we've much to learn with these drugs. It's a really exciting time.' He went on: 'We want to broaden the ways in which you can access these drugs – so we're very interested in thinking about pharmacies, thinking about digital. 'We will deliver the structured support through a combination of digital and face-to-face. 'But we want to innovate. This can be a model that is not just about GP prescribing, but we need to learn how to do that.'
Powys County Times
35 minutes ago
- Powys County Times
Weight loss jabs could be transformative, says outgoing NHS England official
Weight loss jabs like mounjaro could be as transformative as statins, the NHS's top doctor has said. Cholesterol-busting statins are one of the most commonly prescribed drugs in the UK, with around seven to eight million people taking them to cut their chance of heart attack and stroke. An estimated 1.5 million are taking weight loss jabs in the UK. Professor Sir Stephen Powis, the outgoing medical director of NHS England, said the NHS needs to go 'further and faster' to 'turn the tide' on rising levels of obesity. Later this month GPs in England will be allowed to prescribe mounjaro, also known as tirzepatide, for the first time. Patients previously needed to access the drugs through a special weight loss service. Speaking at the NHS ConfedExpo conference in Manchester, Sir Stephen hailed the rollout in GP surgeries as an 'exciting milestone' and said NHS officials are also examining ways to 'broaden access to the drugs'. Around 29% of adults in the UK are obese. Sir Stephen said: 'Right now, obesity is estimated to cost the NHS approximately £11.4 billion every year – this financial burden is unsustainable for the NHS and wider economy. 'We have to turn the tide. We have to and will go further, and faster. 'In just a few years from now, some of today's weight loss drugs will be available at much lower cost. This could completely transform access to these innovative treatments. 'But we will and must be guided by the evidence base and must do this safely and sustainably, in a way that ensures that we are equipped as a health service to deal with the demand.' He said he is not 'starry-eyed' about weight loss drugs, adding they are 'no silver bullet'. He told reporters: 'These medicines can be harmful if they are prescribed without the right checks and wraparound care – they can have side effects, including nausea, dehydration and inflammation of the pancreas, and a worrying number of people are continuing to access them without appropriate checks via the internet. 'We are ambitious and determined to explore different methods of delivery and strengthen the evidence base and will do so alongside this phased rollout, but this is a historic first step in widening access, with 220,000 people set to benefit from the rollout over the first three years. 'So I think over time it's highly likely that they will become more widespread, the evidence base will increase, we will learn better how to deploy them, we'll learn how long people need to be on them, and in terms of weight reduction, how much weight reduction is maintained once people come off – that's a big unknown. 'We see this every time we have a new class of drugs in the early days. But there's still much more to learn. 'There will be more drugs coming on the market; there will be different prices for drugs, we will get to generics, which means that prices will fall. 'We have been through this with statins, and the use of statins is now very different from when they first came out, and I've no doubt that will be the same for these drugs. 'So it's very exciting, but we're in the foothills of learning how to use them.' Asked about statins, Sir Stephen said: 'So firstly, obesity is associated with a whole set of conditions (such as) kidney disease, cardiovascular disease, respiratory conditions. 'So in reducing weight, you will, by the very nature of doing that, be reducing the risk of a whole set of difficult conditions and aiding with their management where people already have them. 'Whether the drugs have effects beyond that, I think, is a research question, and there will be an evidence base being generated. 'And it's not completely unusual for drugs over time to be found to have effects that go over and beyond what they were initially designed for. 'So I think we will wait and see. But obviously, the first task, amongst all the excitement and all the discussion and debate, is to actually get on and deploy tirzepatide in particular. 'We have been focused on getting this rolled out by the end of this month… and that is going to be a really exciting milestone. 'It's going to be a very exciting journey, and there will be things on the way that we haven't expected.' He added: 'We set out the our plan for uptake – Nice (National Institute for Health and Care Excellence) have asked for a review of that after three years, which is quite right, because it's quite a long horizon. 'Cost is one element of that, but I think we will learn more about the outcomes that these drugs are driving in terms of lower cardiovascular events and reducing the conditions that we know associated with obesity. 'So absolutely, cost is one element of that, but it's not the only element. We want to look carefully at what the science tells us.' Sir Stephen added: 'When I look back when dialysis came in, we didn't use dialysis for older people. Over years the technology improved, we got more confident, more people were able to access the treatment. 'So we've much to learn with these drugs. It's a really exciting time.' He went on: 'We want to broaden the ways in which you can access these drugs – so we're very interested in thinking about pharmacies, thinking about digital. 'We will deliver the structured support through a combination of digital and face-to-face. 'But we want to innovate. This can be a model that is not just about GP prescribing, but we need to learn how to do that.'
Leader Live
38 minutes ago
- Leader Live
Weight loss jabs could be transformative, says outgoing NHS England official
Cholesterol-busting statins are one of the most commonly prescribed drugs in the UK, with around seven to eight million people taking them to cut their chance of heart attack and stroke. An estimated 1.5 million are taking weight loss jabs in the UK. Professor Sir Stephen Powis, the outgoing medical director of NHS England, said the NHS needs to go 'further and faster' to 'turn the tide' on rising levels of obesity. Later this month GPs in England will be allowed to prescribe mounjaro, also known as tirzepatide, for the first time. Patients previously needed to access the drugs through a special weight loss service. Speaking at the NHS ConfedExpo conference in Manchester, Sir Stephen hailed the rollout in GP surgeries as an 'exciting milestone' and said NHS officials are also examining ways to 'broaden access to the drugs'. Around 29% of adults in the UK are obese. Sir Stephen said: 'Right now, obesity is estimated to cost the NHS approximately £11.4 billion every year – this financial burden is unsustainable for the NHS and wider economy. 'We have to turn the tide. We have to and will go further, and faster. 'In just a few years from now, some of today's weight loss drugs will be available at much lower cost. This could completely transform access to these innovative treatments. 'But we will and must be guided by the evidence base and must do this safely and sustainably, in a way that ensures that we are equipped as a health service to deal with the demand.' He said he is not 'starry-eyed' about weight loss drugs, adding they are 'no silver bullet'. He told reporters: 'These medicines can be harmful if they are prescribed without the right checks and wraparound care – they can have side effects, including nausea, dehydration and inflammation of the pancreas, and a worrying number of people are continuing to access them without appropriate checks via the internet. 'We are ambitious and determined to explore different methods of delivery and strengthen the evidence base and will do so alongside this phased rollout, but this is a historic first step in widening access, with 220,000 people set to benefit from the rollout over the first three years. 'So I think over time it's highly likely that they will become more widespread, the evidence base will increase, we will learn better how to deploy them, we'll learn how long people need to be on them, and in terms of weight reduction, how much weight reduction is maintained once people come off – that's a big unknown. 'We see this every time we have a new class of drugs in the early days. But there's still much more to learn. 'There will be more drugs coming on the market; there will be different prices for drugs, we will get to generics, which means that prices will fall. 'We have been through this with statins, and the use of statins is now very different from when they first came out, and I've no doubt that will be the same for these drugs. 'So it's very exciting, but we're in the foothills of learning how to use them.' Asked about statins, Sir Stephen said: 'So firstly, obesity is associated with a whole set of conditions (such as) kidney disease, cardiovascular disease, respiratory conditions. 'So in reducing weight, you will, by the very nature of doing that, be reducing the risk of a whole set of difficult conditions and aiding with their management where people already have them. 'Whether the drugs have effects beyond that, I think, is a research question, and there will be an evidence base being generated. 'And it's not completely unusual for drugs over time to be found to have effects that go over and beyond what they were initially designed for. 'So I think we will wait and see. But obviously, the first task, amongst all the excitement and all the discussion and debate, is to actually get on and deploy tirzepatide in particular. 'We have been focused on getting this rolled out by the end of this month… and that is going to be a really exciting milestone. 'It's going to be a very exciting journey, and there will be things on the way that we haven't expected.' He added: 'We set out the our plan for uptake – Nice (National Institute for Health and Care Excellence) have asked for a review of that after three years, which is quite right, because it's quite a long horizon. 'Cost is one element of that, but I think we will learn more about the outcomes that these drugs are driving in terms of lower cardiovascular events and reducing the conditions that we know associated with obesity. 'So absolutely, cost is one element of that, but it's not the only element. We want to look carefully at what the science tells us.' Sir Stephen added: 'When I look back when dialysis came in, we didn't use dialysis for older people. Over years the technology improved, we got more confident, more people were able to access the treatment. 'So we've much to learn with these drugs. It's a really exciting time.' He went on: 'We want to broaden the ways in which you can access these drugs – so we're very interested in thinking about pharmacies, thinking about digital. 'We will deliver the structured support through a combination of digital and face-to-face. 'But we want to innovate. This can be a model that is not just about GP prescribing, but we need to learn how to do that.'
